Bicara Therapeutics (NASDAQ:BCAX) CFO Sells $330,097.25 in Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) CFO Ivan Hyep sold 17,795 shares of the company’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $18.55, for a total transaction of $330,097.25. Following the transaction, the chief financial officer directly owned 145,355 shares in the company, valued at $2,696,335.25. The trade was a 10.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

Ivan Hyep also recently made the following trade(s):

• On Friday, November 21st, Ivan Hyep sold 605 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.15, for a total transaction of $10,980.75.
• On Thursday, October 9th, Ivan Hyep sold 6,415 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.23, for a total value of $116,945.45.
• On Tuesday, October 7th, Ivan Hyep sold 18,244 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.22, for a total value of $332,405.68.
• On Wednesday, October 8th, Ivan Hyep sold 5,627 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.21, for a total value of $102,467.67.
• On Monday, October 6th, Ivan Hyep sold 6,514 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.17, for a total value of $118,359.38.

Bicara Therapeutics Stock Performance

Shares of NASDAQ:BCAX traded down $0.42 during mid-day trading on Tuesday, hitting $18.46. 1,136,579 shares of the company traded hands, compared to its average volume of 608,772. The firm’s 50 day simple moving average is $15.45 and its 200 day simple moving average is $12.65. The firm has a market cap of $1.01 billion, a P/E ratio of -8.24 and a beta of -0.76. Bicara Therapeutics Inc. has a 52-week low of $7.80 and a 52-week high of $22.67.

Bicara Therapeutics (NASDAQ:BCAX) last released its quarterly earnings results on Monday, November 10th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.12). Equities research analysts expect that Bicara Therapeutics Inc. will post -2.59 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Wells Fargo & Company boosted their price objective on shares of Bicara Therapeutics from $8.00 to $11.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Tuesday, October 14th. Wedbush reaffirmed an “outperform” rating and issued a $30.00 target price on shares of Bicara Therapeutics in a research report on Monday, November 10th. Piper Sandler initiated coverage on Bicara Therapeutics in a research note on Monday, August 18th. They set an “overweight” rating and a $36.00 target price for the company. Finally, HC Wainwright decreased their price target on shares of Bicara Therapeutics from $41.00 to $40.00 and set a “buy” rating for the company in a research report on Friday, August 22nd. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Bicara Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $29.67.

Hedge Funds Weigh In On Bicara Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. CWM LLC acquired a new stake in shares of Bicara Therapeutics during the 1st quarter worth approximately $29,000. Legal & General Group Plc increased its position in Bicara Therapeutics by 64.1% in the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after buying an additional 1,233 shares during the period. Ameritas Investment Partners Inc. increased its position in Bicara Therapeutics by 73.0% in the second quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock worth $32,000 after buying an additional 1,474 shares during the period. Larson Financial Group LLC boosted its holdings in shares of Bicara Therapeutics by 1,015.5% during the third quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock valued at $62,000 after acquiring an additional 3,595 shares during the period. Finally, New York State Common Retirement Fund acquired a new position in shares of Bicara Therapeutics during the first quarter valued at $52,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.